BioCentury
ARTICLE | Clinical News

Genentech reports Phase II data for sustained delivery eye implant of ranibizumab

August 17, 2018 3:12 AM UTC

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) said the majority of patients who received Port Delivery System (PDS) administration of ranibizumab were able to go six months or longer between implantation and the first required refill of the PDS implant in the Phase II LADDER trial to treat wet age-related macular degeneration (AMD). Data were presented at the American Society of Retina Specialists meeting in Vancouver.

The PDS is a small, refillable device that is surgically implanted in the eye to continuously deliver a specialized formulation of ranibizumab. It is refilled using a customized needle in a minimally invasive office-based procedure...